Dipyridamole Ameliorates Memory Impairment and Increases Hippocampal Calbindin Expression in Niemann Pick C1 Mice
Journal of Neuroscience Research · 2024
DOI: 10.1002/jnr.70011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuroscience Research, 2024. Verfasst von Lucia Gaddini und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy. Hauptthemen laut MEDLINE: Hippocampus, Niemann-Pick Disease, Type C, Dipyridamole, Memory Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Istituto Superiore di Sanità.
Abstract (Originalsprache)
Niemann Pick type C1 (NPC1) is a rare, fatal disorder characterized by endosomal lipid accumulation that leads to damage of both peripheral organs and central nervous system (cerebellum and hippocampus are especially affected). Currently, miglustat is the only approved drug for NPC1, thus the identification of new treatments is mandatory. We have previously demonstrated that the drug dipyridamole (DIP), an enhancer of adenosine signaling, can reduce the pathological phenotype in patient‐derived fibroblasts. In this paper, we evaluated the in vivo effects of DIP in NPC1 mice. Male and female NPC1 nih mice were treated with DIP 30 mg/kg i.p. from 28 to 64 days of age. Motor function was assessed by Erasmus Ladder test, hippocampal cognitive decline by Novel Object Recognition test and brain pathology by immunofluorescence and biochemical assays. Peripheral pathology was evaluated by analyzing lipid accumulation in spleen and liver (HP‐TLC). In NPC1, mice DIP rescued recognition memory and increased hippocampal expression of calbindin. On the contrary, the drug was unable to improve motor function, cerebellar pathology and lipid accumulation in spleen and liver. Our results demonstrated that DIP selectively ameliorates the cognitive impairment in NPC1 mice. This drug could thus represent a valuable therapeutic tool to be used in combination with other treatments in NPC1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.
- University of Lille, Inserm, CHU Lille, UMR-S1172 Lille Neuroscience & Cognition (LilNCog), Lille, France.
- Alzheimer and Tauopathies, LabEx DISTALZ, Lille, France.
- Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
- Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanità, Rome, Italy.
ORCID-Profile: Antonella Ferrante
Förderung
- Istituto Superiore di Sanità
Zitieren
APA
Gaddini, L., Chiodi, V., Matteucci, A., Boussadia, Z., Buée, L., Eddarkaoui, S., Blum, D., Di Carlo, N., Raggi, C., Di Benedetto, R., Popoli, P., & Ferrante, A. (2024). Dipyridamole Ameliorates Memory Impairment and Increases Hippocampal Calbindin Expression in Niemann Pick C1 Mice. Journal of Neuroscience Research. https://doi.org/10.1002/jnr.70011
Vancouver
Gaddini L, Chiodi V, Matteucci A, Boussadia Z, Buée L, Eddarkaoui S, et al. Dipyridamole Ameliorates Memory Impairment and Increases Hippocampal Calbindin Expression in Niemann Pick C1 Mice. Journal of Neuroscience Research. 2024. doi:10.1002/jnr.70011
BibTeX
@article{Gaddini2024,
author = {Gaddini, Lucia and Chiodi, Valentina and Matteucci, Andrea and Boussadia, Zaira and Buée, Luc and Eddarkaoui, Sabiha and Blum, David and Di Carlo, Nazzareno and Raggi, Carla and Di Benedetto, Rita and Popoli, Patrizia and Ferrante, Antonella},
title = {Dipyridamole Ameliorates Memory Impairment and Increases Hippocampal Calbindin Expression in Niemann Pick C1 Mice},
journal = {Journal of Neuroscience Research},
year = {2024},
doi = {10.1002/jnr.70011}
}
EUVIMED